FDA “Critical Path” Will Emphasize Clinical Trial Simulation For Drugs
Executive Summary
FDA's "Critical Path" initiative will encourage drug manufacturers to use computer modeling to improve clinical trial design, Acting Deputy Commissioner for Operations Janet Woodcock, MD, said
You may also be interested in...
Computer Simulations Of Clinical Trials To Be Addressed In FDA Guidance
FDA plans to address the use of computer simulation models in an upcoming guidance on issues firms should consider at the end of Phase IIa
Computer Simulations Of Clinical Trials To Be Addressed In FDA Guidance
FDA plans to address the use of computer simulation models in an upcoming guidance on issues firms should consider at the end of Phase IIa
FDA Will Publish “Critical Path” Opportunities List By Fall, Woodcock Says
FDA plans to finalize its list of "Critical Path" opportunities by early fall, Acting Deputy Commissioner for Operations Janet Woodcock said